Trial reportEpilepsia2025
Distinct impacts of sodium channel blockers on the strength-duration properties of human motor cortex neurons.
Trial report in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Distinct impacts of sodium channel blockers on the strength-duration properties of human motor cortex neurons.Epilepsia · 2025Trial
- Mechanisms of transcranial magnetic brain stimulation.Physiological reviews · 2026Review
- Investigating Neuropharmacological Features of the Cortical Activity of Cannabidiol GWP42003 P-A Phase 1 Clinical Trial.Brain sciences · 2026Article
- Electrophysiological Evaluation of Post-Activation Potentiation/Post-Activation Performance Enhancement Using Strength-Duration Properties.Journal of functional morphology and kinesiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study was undertaken to determine how voltage-gated sodium channel (VGSC) blockers modulate cortical excitability in vivo. VGSCs are critical for regulating axonal excitability, yet the effects of sodium channel-blocking medications on human cortical neurons remain poorly characterized. We aimed to address this gap using transcranial magnetic stimulation (TMS)-derived strength-duration measures as a noninvasive index of VGSC function.
methodsThirteen healthy adults received single doses of either carbamazepine, lacosamide, or placebo in a crossover design. TMS was used to assess changes in resting motor threshold and strength-duration properties, including rheobase and the strength-duration time constant, as indices of VGSC function.
resultsBoth medications elevated resting motor thresholds compared to placebo, indicating reduced excitability; however, their impacts varied according to TMS pulse width. Carbamazepine raised thresholds proportionally across all pulse widths, whereas lacosamide disproportionately influenced thresholds. Crucially, lacosamide reduced the strength-duration time constant and increased rheobase, whereas carbamazepine had minimal effects on both measures. SIGNIFICANCE: These results reveal subtle and unexpected differences in cortical neuron behavior following VGSC-blocking medication administration. Lacosamide's response aligns with the proposed mechanism of sodium conductance blockade, whereas carbamazepine's effects suggest distinct VGSC interactions or potential off-target effects. Our findings advance the understanding of VGSC-blocking medication interactions in the human cortex and underscore the importance of employing specific TMS measures to gain deeper insights into medication mechanisms of action in vivo. Such measures could serve as valuable adjuncts in medication development and patient monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.